We are live on ! Find out more
TNDM icon

Tandem Diabetes Care

200 hedge funds and large institutions have $1.81B invested in Tandem Diabetes Care in 2018 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 74 increasing their positions, 57 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 30

45% more call options, than puts

Call options by funds: $56.2M | Put options by funds: $38.8M

30% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 57

10.98% more ownership

Funds ownership: 72.15%83.13% (+11%)

9% more funds holding

Funds holding: 184200 (+16)

2% more capital invested

Capital invested by funds: $1.77B → $1.81B (+$42.2M)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

Holders
200
Holders Change
+16
Holders Change %
+8.7%
% of All Funds
4.46%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.16%
New
46
Increased
74
Reduced
57
Closed
30
Calls
$56.2M
Puts
$38.8M
Net Calls
+$17.4M
Net Calls Change
-$34.5M
Name Holding Trade Value Shares
Change
Change in
Stake
DM
26
Deerfield Management
New York
$21M +$9.56M +270,650 +96%
AQR Capital Management
27
AQR Capital Management
Connecticut
$20.5M +$5.7M +161,526 +43%
Goldman Sachs
28
Goldman Sachs
New York
$19.6M -$9.9M -280,280 -35%
DCM
29
Daruma Capital Management
New York
$18.9M +$17.6M +498,957 New
HRCM
30
Hood River Capital Management
Florida
$17.3M +$201K +5,678 +1%
Baillie Gifford & Co
31
Baillie Gifford & Co
United Kingdom
$16.5M
WA
32
Wasatch Advisors
Utah
$14.1M +$827K +23,426 +7%
DCM
33
Driehaus Capital Management
Illinois
$13.3M +$4.88M +138,206 +65%
Ameriprise
34
Ameriprise
Minnesota
$12.1M +$1.03M +29,048 +10%
Charles Schwab
35
Charles Schwab
California
$11.4M -$40.1K -1,137 -0.4%
CM
36
Castleark Management
Illinois
$10.6M -$2.53M -71,670 -20%
FLAM
37
First Light Asset Management
Minnesota
$10M
WRF
38
Waddell & Reed Financial
Kansas
$9.98M +$9.28M +262,793 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$9.5M +$1.39M +39,264 +19%
TGHSA
40
TPG Group Holdings (SBS) Advisors
Texas
$9.48M
SSA
41
Schonfeld Strategic Advisors
New York
$8.81M -$21.1M -597,277 -72%
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$8.63M -$689K -19,502 -8%
OAM
43
Oberweis Asset Management
Illinois
$8.54M -$6.71K -190 -0.1%
SAM
44
Sectoral Asset Management
Quebec, Canada
$7.71M +$5.65M +160,100 +373%
Fidelity Investments
45
Fidelity Investments
Massachusetts
$7.68M +$2.05M +58,052 +40%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$7.65M +$4.72M +133,770 +197%
Morgan Stanley
47
Morgan Stanley
New York
$7M -$3.56M -100,856 -35%
WBC
48
Westpac Banking Corp
Australia
$6.46M +$1.01M +28,700 +20%
VOYA Investment Management
49
VOYA Investment Management
Georgia
$5.79M +$4.69M +132,710 +667%
Bank of America
50
Bank of America
North Carolina
$4.61M +$3.06M +86,763 +250%

TNDM Hedge Fund Activity: Q4 2018 in Review

200 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2018, worth a combined $1.81B — up 2.4% from $1.77B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new TNDM positions and 30 closed out — a net gain of 16 holders — while 74 added to existing stakes and 57 trimmed.

The largest buyer was Vanguard Group, adding an estimated $66M. The largest seller was Hitchwood Capital Management, exiting entirely with an estimated $24.4M sold.

  • 200 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2018, up from 184 in Q3 2018.
  • Funds reported $1.81B of Tandem Diabetes Care stock for Q4 2018, up 2.4% quarter-over-quarter.
  • 46 funds opened new Tandem Diabetes Care positions in Q4 2018 and 30 closed out, a net change of +16 holders.
  • The largest Tandem Diabetes Care buyer in Q4 2018 was Vanguard Group, an estimated $66M added.
  • The largest Tandem Diabetes Care seller in Q4 2018 was Hitchwood Capital Management, an estimated $24.4M sold.

Based on aggregated 13F filings for Q4 2018.